On May 25, 2023, Geron, a leading biopharmaceutical company, made a significant announcement regarding its latest research findings. The company revealed that it will be presenting Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial at the 2023 American Society of Clinical Oncology Annual Meeting. The IMerge Phase 2/3 study is a double-blind, 2:1 randomized, placebo-controlled clinical trial that aims to evaluate the effectiveness of imetelstat in transfusion-dependent patients with lower-risk MDS who are relapsed or refractory to erythropoiesis-stimulating agents. The results of the study have shown a significant improvement in continuous transfusion independence observed in imetelstat-treated lower-risk MDS patients in IMerge Phase 3.
Moreover, Geron also announced that the combination of REQORSA® and Tagrisso® was well tolerated at all three dose levels of the Phase 1 trial, with promising evidence of efficacy observed. However, it’s important to note that this announcement is not related to the upcoming oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting.
GERN Stock Update: May 25, 2023 – Biotech Company Specializing in Cancer Therapies with $1.6 Billion Market Capitalization
On May 25, 2023, GERN stock opened at $3.16 and experienced a day’s range of $3.06 to $3.17. The volume for the day was 194,909, and the market capitalization of the company was $1.6 billion. GERN is a biotechnology company that specializes in developing therapies for cancer and other diseases. The company’s earnings growth for the last year was -5.14%, while its earnings growth for this year was -0.90%. GERN’s next reporting date is scheduled for August 2, 2023, with an EPS forecast of -$0.08 for the quarter. The company operates in the health technology industry, specifically in the biotechnology sector, and its corporate headquarters are located in Foster City, California.
Geron Corps Stock Performance Shows Promising Growth Potential in Biotech Industry
On May 25, 2023, Geron Corp’s stock performance was closely watched by investors and analysts alike. According to data from CNN Money, the six analysts who offered 12-month price forecasts for the company had a median target of $5.00, with a high estimate of $6.00 and a low estimate of $4.00. This median estimate represented a +58.98% increase from the last price of $3.15. The current consensus among the six polled investment analysts was to buy stock in Geron Corp, a rating that had held steady since March, when it was unchanged from a buy rating. Geron Corp is a biotechnology company that specializes in developing therapies for cancer and other diseases using its proprietary technology platforms. The company’s lead drug candidate, imetelstat, is currently in clinical trials for the treatment of myelodysplastic syndromes (MDS) and myelofibrosis (MF).
Read more here: Source link